基于性别的激素对喘生物标志物的影响
Ishitha Jagadish1, Divya Shah1, Jennifer Priessnitz2
1Department of Internal Medicine, University of Arizona, Phoenix, AZ, USA.
The Journal of allergy and clinical immunology
|January 16, 2026
概括
喘显示出显著的性别差异,男孩具有更高的乙氨基和IgE水平,而成年女性则经历了更大的严重程度. 了解这些性别特异性喘生物标志物是个性化治疗的关键.
科学领域:
- 肺病学和免疫学 肺病学和免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- 喘在美国影响了2500万人,在患病率,表型和治疗方面存在显著的性别差异.
- 与男孩相比,荷尔蒙和免疫因素有助于增加成人女性的喘严重程度.
研究的目的:
- 审查有关喘生物标志物性别特异现有证据.
- 探索驱动这些变化的潜在机制.
主要方法:
- 文献综述综合了关于喘生物标志物的研究.
- 对BEC,FeNO,IGE,IL-5等生物标志物的性别分层数据的分析.
主要成果:
- 患有喘的男孩表现出更高的血中乙氨基细胞计数 (BECs),部分呼出的氧化 (FeNO) 和免疫球蛋白E (IgE).
- 青春期后的女性表现出增加的IL-5 (IL-5) 和其他标记物,而男性显示出更高的胺度.
结论:
- 性激素会影响喘时的免疫反应,影响生物标志物概况.
- 经过验证的性别特异性生物标志物可以改善喘表型和个性化管理策略.
关键词:
它们有IL-13和IL-13.IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL is is is is is is is is is is is what you are is what you are在IL-5中,IL-5是最常见的.亚迪波基因 (Adipokine) 是一种可靠的药物.没有任何的Adiponectin.喘 喘 是一种基细胞激活标志物的标志物化学物质 (chemokines) 是一种化学物质.奇丁酶-3类蛋白 1 类似蛋白 1半乙烯 (cysteinyl leukotrienes) 是一种类型的蛋白质.细胞因子 细胞因子埃索诺菲尔细胞的存在呼出的呼吸凝聚剂标记器部分排出的氧化氧化物.性别 性别 性别 性别 性别免疫球体蛋白E 免疫球体蛋白E勒普丁是一种素.这是一个微型RNA.骨髓氧化酶是如何形成的中性粒细胞弹性酶.皮里奥斯的时间.血清中的粉样蛋白A.在性爱中,性爱是性爱.性别差异的性别差异.性激素 性激素 性激素斯芬戈-1-酸盐是一种酸盐.表面活性蛋白质的表面活性蛋白质.试酸酶的使用方法相关概念视频
Asthma-I: Introduction
3.4K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.4K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K


